\begin{table}[htbp]
\centering
\caption{First Stage: Effect of Must-Access PDMP Mandates on Opioid Prescribing}
\label{tab:first_stage}
\small
\begin{tabular}{llccc}
\toprule
Specification & Outcome & ATT & SE & 95\% CI \\
\midrule
\multicolumn{5}{l}{\textit{Panel A: Overall ATT}} \\
Callaway-Sant'Anna & Rx rate per 100 & -9.49 & (3.28) & [-15.92, -3.07] \\
Callaway-Sant'Anna & Log(Rx rate) & -0.1385 & (0.0273) & [-0.1919, -0.0851] \\
TWFE & Rx rate per 100 & -5.20 & (1.59) & [-8.31, -2.09] \\
TWFE & Log(Rx rate) & -0.0722 & (0.0214) & [-0.1141, -0.0302] \\
\midrule
\multicolumn{5}{l}{\textit{Panel B: Group-level ATT (CS-DiD, Rx rate per 100)}} \\
Cohort 2013 & Rx rate per 100 & -30.68*** & (8.86) & [-48.05, -13.32] \\
Cohort 2014 & Rx rate per 100 & -3.92 & (11.18) & [-25.84, 17.99] \\
Cohort 2015 & Rx rate per 100 & -9.00** & (4.30) & [-17.42, -0.57] \\
Cohort 2016 & Rx rate per 100 & -7.64** & (3.67) & [-14.84, -0.43] \\
Cohort 2017 & Rx rate per 100 & -9.05** & (3.63) & [-16.16, -1.94] \\
Cohort 2018 & Rx rate per 100 & -6.87** & (2.76) & [-12.27, -1.46] \\
Cohort 2019 & Rx rate per 100 & -5.27 & (3.34) & [-11.82, 1.28] \\
\bottomrule
\end{tabular}
\begin{minipage}{0.95\textwidth}
\vspace{0.3cm}
\footnotesize
\textit{Notes:} This table reports first-stage estimates of the effect of must-access PDMP mandates
on opioid prescribing rates (dispensing rate per 100 persons). Panel~A shows overall ATT estimates
from both Callaway-Sant'Anna (2021) and two-way fixed effects specifications. Panel~B reports
cohort-specific ATT estimates from the CS-DiD estimator. The comparison group consists of
not-yet-treated states, consistent with the main employment analysis. Standard errors are computed
via multiplier bootstrap (1,000 iterations) with one year of anticipation. Opioid prescribing data
from CDC state-level reports (CDC/IQVIA Xponent), restricted to years with observed state-level
data (2006--2019). $N = 686$ state-years (49 states $\times$ 14 years); 45 treated states,
4 never-treated (KS, MO, NE, SD). One state is excluded due to missing CDC prescribing data.
The 2020 and 2021 adoption cohorts (TX, MT, ID, WY) are omitted from Panel~B because
the prescribing data end in 2019, providing zero post-treatment observations for these cohorts;
these states contribute as not-yet-treated controls for earlier cohorts.
$^{***}p<0.01$, $^{**}p<0.05$, $^{*}p<0.1$.
\end{minipage}
\end{table}
